XEN45

DEVICE2 trials

Sponsors

Allergan, Paracelsus Medical University

Conditions

Angle-ClosureEndothelial Cell Loss, CornealGlaucoma

Phase 3

Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma

CompletedNCT03362931

AllerganAngle-Closure, Glaucoma

Start: 2018-07-19End: 2022-03-18Updated: 2023-05-17

Unknown Phase

Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation

CompletedNCT04547036

Paracelsus Medical UniversityEndothelial Cell Loss, Corneal, Glaucoma

Start: 2020-01-30End: 2021-04-30Updated: 2021-07-13